Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""HEPATITIS B"" wg kryterium: Temat


Tytuł :
Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy.
Autorzy :
Ditto MC; Rheumatology Unit, Department of General and Specialistic Medicine, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, and University of Padova, PhD Program in Clinical and Experimental Sciences, Padova, Italy.
Parisi S; Rheumatology Unit, Department of General and Specialistic Medicine, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy. .
Varisco V; Rheumatology Unit, Department of Internal Medicine, San Gerardo Hospital, Monza, Italy.
Talotta R; Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Messina, Azienda Ospedaliera Gaetano Martino, Messina, Italy.
Batticciotto A; Rheumatology Unit, Department of Internal Medicine, Ospedale di Circolo - Fondazione Macchi, ASST-Settelaghi, Varese, Italy.
Antivalle M; Rheumatology Unit, University Hospital ASST-Fatebenefratelli-Sacco, Milan, Italy.
Gerardi MC; Rheumatology and Clinical Immunology Unit and Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Italy.
Agosti M; Rheumatology Unit, University Hospital ASST-Fatebenefratelli-Sacco, Milan, Italy.
Borrelli R; Rheumatology Unit, Department of General and Specialistic Medicine, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
Fusaro E; Rheumatology Unit, Department of General and Specialistic Medicine, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
Sarzi-Puttini P; Rheumatology Unit, University Hospital ASST-Fatebenefratelli-Sacco, Milan, Italy.
Pokaż więcej
Źródło :
Clinical and experimental rheumatology [Clin Exp Rheumatol] 2021 May-Jun; Vol. 39 (3), pp. 546-554. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Hepatitis B*/diagnosis
Hepatitis B*/drug therapy
Hepatitis B*/epidemiology
Hepatitis B virus*
Tumor Necrosis Factor Inhibitors*/immunology
Tumor Necrosis Factor Inhibitors*/therapeutic use
Virus Activation*
Antiviral Agents/*therapeutic use
Arthritis, Rheumatoid/*immunology
Arthritis, Rheumatoid/therapy ; Biological Therapy ; Hepatitis B Antibodies/pharmacology ; Hepatitis B Antibodies/therapeutic use ; Hepatitis B Surface Antigens ; Humans ; Prevalence
Czasopismo naukowe
Tytuł :
Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Autorzy :
Yamauchi N; Department of Hematology, National Cancer Center East Hospital, Kashiwa, Japan.
Maruyama D; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Choi I; Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Sakai R; Department of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Miyashita K; Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
Moriuchi Y; Department of Hematology, Sasebo City General Hospital, Sasebo, Japan.
Tsujimura H; Division of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.
Kubota N; Department of Hematology, Saitama Cancer Center, Saitama, Japan.
Yamamoto G; Department of Hematology, Toranomon Hospital, Tokyo, Japan.
Igarashi T; Department of Hematology, Gunma Prefectural Cancer Center, Gunma, Japan.
Izutsu K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Yoshida S; Department of Hematology, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan.
Kojima K; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Uchida T; Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.
Inoue Y; Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Tsukamoto N; Department of Hematology, Gunma University Hospital, Maebashi, Japan.
Ohtsuka E; Department of Hematology, Oita prefectural Hospital, Oita, Japan.
Suzuki S; Department of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Inaguma Y; Division of Hematology, Fujita Health University, Toyoake, Japan.
Ichikawa S; Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Gomyo H; Division of Hematology, Hyogo Cancer Center, Akashi, Japan.
Ushijima Y; Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nosaka K; Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.
Kurata M; Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Tanaka Y; Department of Virology and Liver unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.; Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Ueda R; Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagakute, Japan.
Mizokami M; Genome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Japan.
Kusumoto S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2021 May; Vol. 112 (5), pp. 1943-1954. Date of Electronic Publication: 2021 Mar 18.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Antiviral Agents/*therapeutic use
Hepatitis B/*drug therapy
Hepatitis B Surface Antigens/*blood
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Rituximab/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Alanine Transaminase/blood ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Case-Control Studies ; Cyclophosphamide/administration & dosage ; DNA, Viral/blood ; Doxorubicin/administration & dosage ; Doxorubicin/analogs & derivatives ; Female ; Hepatitis B/blood ; Hepatitis B/epidemiology ; Hepatitis B virus/genetics ; Humans ; Incidence ; Induction Chemotherapy/methods ; Japan/epidemiology ; Liver Function Tests ; Lymphoma, Large B-Cell, Diffuse/blood ; Lymphoma, Large B-Cell, Diffuse/immunology ; Lymphoma, Large B-Cell, Diffuse/virology ; Male ; Middle Aged ; Prednisone/administration & dosage ; Retrospective Studies ; Rituximab/administration & dosage ; Survival Analysis ; Vincristine/administration & dosage ; Virus Activation
Czasopismo naukowe
Tytuł :
Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study.
Autorzy :
Boglione L; Department of Translational Medicine (DiMET), University of Eastern Piedmont, Via Solaroli 17, 28100, Novara, Italy. .
De Benedetto I; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.
Lupia T; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.
Cusato J; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.
Cariti G; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.
Di Perri G; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.
Pokaż więcej
Źródło :
Archives of virology [Arch Virol] 2021 Apr; Vol. 166 (4), pp. 1125-1131. Date of Electronic Publication: 2021 Feb 12.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Antiviral Agents/*therapeutic use
Guanine/*analogs & derivatives
Hepatitis B virus/*drug effects
Hepatitis B, Chronic/*drug therapy
Tenofovir/*therapeutic use
Adult ; Female ; Genotype ; Guanine/therapeutic use ; Hepatitis B Surface Antigens/blood ; Hepatitis B virus/genetics ; Hepatitis B, Chronic/virology ; Humans ; Male ; Prospective Studies ; Treatment Outcome ; Viral Load/drug effects ; Young Adult
Czasopismo naukowe
Tytuł :
Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B.
Autorzy :
Farag MS; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada.; Institute of Medical Science, University of Toronto, Toronto, Canada.
van Campenhout MJH; Department of Gastroenterology and Hepatology, Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands.
Pfefferkorn M; University Hospital Leipzig, Department of Gastroenterology and Rheumatology, Section of Hepatology, Leipzig, Germany.
Fischer J; University Hospital Leipzig, Department of Gastroenterology and Rheumatology, Section of Hepatology, Leipzig, Germany.
Deichsel D; University Hospital Leipzig, Department of Gastroenterology and Rheumatology, Section of Hepatology, Leipzig, Germany.
Boonstra A; Department of Gastroenterology and Hepatology, Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands.
van Vuuren AJ; Department of Gastroenterology and Hepatology, Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands.
Ferenci P; Department of Internal Medicine 3, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Feld JJ; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada.
Berg T; University Hospital Leipzig, Department of Gastroenterology and Rheumatology, Section of Hepatology, Leipzig, Germany.
Hansen BE; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada.; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
van Bömmel F; University Hospital Leipzig, Department of Gastroenterology and Rheumatology, Section of Hepatology, Leipzig, Germany.
Janssen HLA; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada.
Pokaż więcej
Źródło :
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Jan 27; Vol. 72 (2), pp. 202-211.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hepatitis B virus*/genetics
Hepatitis B, Chronic*/diagnosis
Hepatitis B, Chronic*/drug therapy
Antiviral Agents/*therapeutic use
Interferon-alpha/*therapeutic use
Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; Humans ; Polyethylene Glycols/therapeutic use ; RNA, Viral/analysis ; Recombinant Proteins/therapeutic use
Czasopismo naukowe
Tytuł :
Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg).
Autorzy :
Lim SG; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Phyo WW; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
Ling JZJ; Singapore Clinical Research Institute, Singapore.
Cloherty G; Abbott Laboratories, Abbott Park, IL, USA.
Butler EK; Abbott Laboratories, Abbott Park, IL, USA.
Kuhns MC; Abbott Laboratories, Abbott Park, IL, USA.
McNamara AL; Abbott Laboratories, Abbott Park, IL, USA.
Holzmayer V; Abbott Laboratories, Abbott Park, IL, USA.
Gersch J; Abbott Laboratories, Abbott Park, IL, USA.
Yang WL; Tan Tock Seng Hospital, Singapore.
Ngu JH; Singapore General Hospital, Singapore.
Chang J; Singapore General Hospital, Singapore.
Tan J; Changi General Hospital, Singapore.
Ahmed T; Khoo Teck Puat Hospital, Singapore.
Dan YY; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Lee YM; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Lee GH; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Tan PS; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
Huang DQ; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Khine HTW; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
Lee C; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
Tay A; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
Chan E; Singapore Clinical Research Institute, Singapore.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jan; Vol. 53 (1), pp. 172-182. Date of Electronic Publication: 2020 Nov 07.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents*/therapeutic use
Hepatitis B, Chronic*/diagnosis
Hepatitis B, Chronic*/drug therapy
Biomarkers ; DNA, Viral ; Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans
Czasopismo naukowe
Tytuł :
Extending treatment eligibility for chronic hepatitis B virus infection.
Autorzy :
McNaughton AL; Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.
Lemoine M; Faculty of Medicine, Department of Metabolism, Digestion and Reproduction, Division of Digestive Diseases, Section of Hepatology and Gastroenterology, Imperial College, London, UK.
van Rensburg C; Division of Gastroenterology, Department of Medicine, Tygerberg Academic Hospital, Cape Town, South Africa.
Matthews PC; Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK. .; Department of Microbiology and Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK. .
Pokaż więcej
Źródło :
Nature reviews. Gastroenterology & hepatology [Nat Rev Gastroenterol Hepatol] 2021 Mar; Vol. 18 (3), pp. 146-147.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Eligibility Determination*
Hepatitis B Vaccines*
Antiviral Agents/*therapeutic use
Hepatitis B, Chronic/*epidemiology
Hepatitis B, Chronic/*prevention & control
Hepatitis B, Chronic/transmission ; Humans
Czasopismo naukowe
Tytuł :
Chronic hepatitis B: identifying who needs to be treated and improving linkage to care.
Autorzy :
Spearman CW; Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa. Electronic address: .
Pokaż więcej
Źródło :
The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2021 Feb; Vol. 6 (2), pp. 83-85. Date of Electronic Publication: 2020 Nov 14.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Antiviral Agents*/therapeutic use
Hepatitis B*
Hepatitis B, Chronic*/diagnosis
Hepatitis B, Chronic*/drug therapy
Hepatitis B virus ; Humans
Czasopismo naukowe
Tytuł :
[Progress in diagnosis and treatment of viral hepatitis in children].
Autorzy :
Chang YN; Department of Infectious Disease, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing 400014, China.
Xu HM; Department of Infectious Disease, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing 400014, China.
Pokaż więcej
Źródło :
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology [Zhonghua Gan Zang Bing Za Zhi] 2021 Jan 20; Vol. 29 (1), pp. 16-20.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents*/therapeutic use
Carcinoma, Hepatocellular*/drug therapy
Hepatitis B*/drug therapy
Hepatitis B, Chronic*/drug therapy
Hepatitis, Viral, Human*/diagnosis
Hepatitis, Viral, Human*/drug therapy
Liver Neoplasms*/drug therapy
Child ; Hepatitis B e Antigens ; Humans ; Liver Cirrhosis/drug therapy
Czasopismo naukowe
Tytuł :
Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection.
Autorzy :
Zhang H; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Hu Y; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Wu M; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Liu J; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Zhu X; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Li X; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Chen H; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Li C; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Liu C; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Niu J; Department of Hepatology, The First Hospital of Jilin University, Jilin, China.
Ding Y; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jan; Vol. 53 (2), pp. 243-252. Date of Electronic Publication: 2020 Nov 28.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents*/adverse effects
Hepatitis B, Chronic*/drug therapy
DNA, Viral ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans ; Leukocytes, Mononuclear ; Tenofovir/adverse effects ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Tytuł :
Good news from WHO on prevention of peripartum hepatitis B transmission.
Autorzy :
Gerlich WH; Institute for Medical Virology, Faculty of Medicine, Justus Liebig University Giessen, D35392 Giessen, Germany. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Infectious diseases [Lancet Infect Dis] 2021 Jan; Vol. 21 (1), pp. 6-8. Date of Electronic Publication: 2020 Aug 14.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Antiviral Agents*/therapeutic use
Hepatitis B*/drug therapy
Child ; Female ; Hepatitis B Surface Antigens ; Hepatitis B virus ; Humans ; Infectious Disease Transmission, Vertical/prevention & control ; Peripartum Period ; Pregnancy ; World Health Organization
Czasopismo naukowe
Tytuł :
Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.
Autorzy :
Brakenhoff SM; Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
de Man RA; Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Boonstra A; Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
van Campenhout MJH; Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
de Knegt RJ; Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
van Bömmel F; Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
van der Eijk AA; Department of Viroscience, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Berg T; Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
Hansen BE; Toronto Center for Liver Disease, Toronto Western and General Hospital, University Health Network, Toronto, ON, Canada.; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
Janssen HLA; Toronto Center for Liver Disease, Toronto Western and General Hospital, University Health Network, Toronto, ON, Canada.
Sonneveld MJ; Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jan; Vol. 53 (2), pp. 314-320. Date of Electronic Publication: 2020 Nov 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents*/therapeutic use
Hepatitis B, Chronic*/drug therapy
Antigens, Viral/therapeutic use ; DNA, Viral ; Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans ; Probability ; RNA/therapeutic use ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Discovery of Novel Pyrimidine-Based Capsid Assembly Modulators as Potent Anti-HBV Agents.
Autorzy :
Kim W; School of Life Science, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Republic of Korea.
Kang JA; Bionanotechnology Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB), Daejeon 34141, Republic of Korea.
Park M; Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang 10408, Republic of Korea.
Jeong PH; School of Life Science, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Republic of Korea.
Kim YJ; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Cho Y; Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang 10408, Republic of Korea.
Park SG; Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Kim YC; School of Life Science, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Republic of Korea.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 May 13; Vol. 64 (9), pp. 5500-5518. Date of Electronic Publication: 2021 Apr 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*chemistry
Capsid Proteins/*metabolism
Hepatitis B virus/*physiology
Pyrimidines/*chemistry
Animals ; Antiviral Agents/metabolism ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Binding Sites ; Capsid Proteins/chemistry ; DNA, Viral/blood ; Drug Evaluation, Preclinical ; Drug Synergism ; Half-Life ; Hepatitis B, Chronic/drug therapy ; Hepatitis B, Chronic/pathology ; Humans ; Male ; Mice ; Mice, Inbred ICR ; Mice, SCID ; Molecular Docking Simulation ; Pyrimidines/metabolism ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use ; Structure-Activity Relationship ; Tenofovir/metabolism ; Tenofovir/pharmacology ; Virus Assembly/drug effects
Czasopismo naukowe
Tytuł :
Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss.
Autorzy :
Yip TC; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.; Medical Data Analytic Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.; Institute of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Wong VW; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.; Medical Data Analytic Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.; Institute of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Tse YK; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.; Medical Data Analytic Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.; Institute of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Liang LY; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Hui VW; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Zhang X; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Li GL; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Lui GC; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.; Medical Data Analytic Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.
Chan HL; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.; Medical Data Analytic Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.; Institute of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Wong GL; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.; Medical Data Analytic Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.; Institute of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jan; Vol. 53 (2), pp. 321-331. Date of Electronic Publication: 2020 Nov 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents*/adverse effects
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/epidemiology
Carcinoma, Hepatocellular*/etiology
Hepatitis B, Chronic*/complications
Hepatitis B, Chronic*/drug therapy
Liver Neoplasms*/drug therapy
Liver Neoplasms*/epidemiology
Liver Neoplasms*/etiology
Adult ; Aged ; DNA, Viral ; Hepatitis B Surface Antigens ; Hong Kong/epidemiology ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Editorial: Biomarkers in HBV and prediction of treatment response - authors' reply.
Autorzy :
Lim SG; Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore.
Pokaż więcej
Corporate Authors :
authors
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jan; Vol. 53 (2), pp. 334.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Antiviral Agents*/therapeutic use
Hepatitis B Surface Antigens*
Biomarkers ; Hepatitis B virus ; Humans
Opinia redakcyjna
Tytuł :
Editorial: biomarkers in HBV and prediction of treatment response.
Autorzy :
Ridruejo E; Hepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas, CEMIC, Ciudad Autónoma de Buenos Aires, Argentina.; Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, Argentina.; Latin American Liver Research Educational and Awareness Network (LALREAN), Pilar, Argentina.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jan; Vol. 53 (2), pp. 332-333.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Antiviral Agents*/therapeutic use
Hepatitis B Surface Antigens*
Biomarkers ; Hepatitis B virus ; Humans
Opinia redakcyjna
Tytuł :
Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.
Autorzy :
Wu Y; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, China.
Huang H; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, China.
Luo Y; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, China.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Feb 04; Vol. 11, pp. 610500. Date of Electronic Publication: 2021 Feb 04 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antiviral Agents/*therapeutic use
Hematopoietic Stem Cell Transplantation/*adverse effects
Hepatitis B/*prevention & control
Hepatitis B virus/*drug effects
Adoptive Transfer ; Biomarkers/blood ; Donor Selection ; Drug Resistance, Viral ; Hepatitis B/immunology ; Hepatitis B/transmission ; Hepatitis B/virology ; Hepatitis B Antibodies/blood ; Hepatitis B Surface Antigens/blood ; Hepatitis B Vaccines/therapeutic use ; Hepatitis B virus/immunology ; Hepatitis B virus/pathogenicity ; Host-Pathogen Interactions ; Humans ; Reinfection ; Risk Factors ; Transplantation, Homologous/adverse effects ; Treatment Outcome ; Virus Activation/drug effects
Czasopismo naukowe
Tytuł :
Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients.
Autorzy :
Huang Q; Assembly Biosciences, Inc., South San Francisco, CA.
Zhou B; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Department of Microbiology and Immunology, Indiana University, Indianapolis, IN.
Cai D; Assembly Biosciences, Inc., South San Francisco, CA.
Zong Y; Assembly Biosciences, Inc., South San Francisco, CA.
Wu Y; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Liu S; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Mercier A; Assembly Biosciences, Inc., South San Francisco, CA.
Guo H; Department of Microbiology and Immunology, Indiana University, Indianapolis, IN.; Cancer Virology Program, UPMC Hillman Cancer Center, Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA.
Hou J; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Colonno R; Assembly Biosciences, Inc., South San Francisco, CA.
Sun J; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Pokaż więcej
Źródło :
Hepatology (Baltimore, Md.) [Hepatology] 2021 Jan; Vol. 73 (1), pp. 41-52. Date of Electronic Publication: 2020 Dec 01.
Typ publikacji :
Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*therapeutic use
DNA, Circular/*drug effects
DNA, Viral/*drug effects
Hepatitis B virus/*drug effects
Hepatitis B, Chronic/*drug therapy
Lamivudine/*therapeutic use
Adolescent ; Adult ; Aged ; Biomarkers/blood ; DNA, Viral/blood ; Female ; Hepatitis B Core Antigens/blood ; Hepatitis B e Antigens/blood ; Hepatitis B virus/genetics ; Hepatitis B, Chronic/genetics ; Hepatitis B, Chronic/virology ; Humans ; Liver/drug effects ; Liver/virology ; Male ; Middle Aged ; Mutation ; Retrospective Studies ; Treatment Outcome ; Viral Load ; Young Adult
Czasopismo naukowe
Tytuł :
Antiviral prophylaxis for hepatitis B carriers affected by diffuse large B cell lymphoma: a matter of survival.
Autorzy :
Zuccaro V; Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Bruno R; Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; Department of Medical, Surgical, Diagnostic and Paediatric Science, University of Pavia, Pavia, Italy.
Arcaini L; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2021 Jan; Vol. 192 (1), pp. 11-12. Date of Electronic Publication: 2020 Oct 31.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents/*therapeutic use
Hepatitis B/*complications
Hepatitis B/*prevention & control
Lymphoma, Large B-Cell, Diffuse/*complications
Antineoplastic Agents, Immunological/therapeutic use ; Hepatitis B/virology ; Hepatitis B virus/drug effects ; Humans ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/virology ; Rituximab/therapeutic use ; Virus Activation/drug effects
Czasopismo naukowe
Tytuł :
Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study.
Autorzy :
Huang HH; Department of Internal Medicine, Division of Hematology, National Taiwan University Hospital, Taipei, Taiwan.
Hsiao FY; Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan.; School of Pharmacy, National Taiwan University, Taipei, Taiwan.; Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.
Chen HM; Health Data Research Center, National Taiwan University, Taipei, Taiwan.
Wang CY; Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan.; School of Pharmacy, National Taiwan University, Taipei, Taiwan.; Department of Pharmacy, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin County, Taiwan.
Ko BS; Department of Internal Medicine, Division of Hematology, National Taiwan University Hospital, Taipei, Taiwan.; Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2021 Jan; Vol. 192 (1), pp. 110-118. Date of Electronic Publication: 2020 Oct 31.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*therapeutic use
Hepatitis B/*complications
Hepatitis B/*drug therapy
Lymphoma, Large B-Cell, Diffuse/*complications
Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Female ; Hepatitis B/diagnosis ; Hepatitis B virus/drug effects ; Humans ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Male ; Middle Aged ; Prednisone/therapeutic use ; Prognosis ; Rituximab/therapeutic use ; Survival Analysis ; Taiwan ; Vincristine/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies